Simmitinib vs chemo for advanced esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called simmitinib against standard chemotherapy for people with advanced esophageal squamous cell carcinoma that has progressed after one prior treatment. The goal is to see if simmitinib works better than chemo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have esophageal squamous cell cancer that cannot be removed by surgery or has spread to other parts of the body.
- You have already received one standard treatment (chemo with immunotherapy) and your cancer has gotten worse.
- You can perform your daily activities with little or no help (ECOG score 0 or 1).
- You have at least one measurable tumor on a scan.
- Your blood counts and organ function (kidney, liver) meet certain levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs—simmitinib (a targeted therapy) and irinotecan (a chemotherapy)—for people with advanced esophageal cancer that has stopped responding to one prior treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests different combinations of treatments given before surgery for a type of esophageal cancer called squamous cell carcinoma. It aims to find the best approach to shrink the tumor and improve outcomes for patients whose cancer has not spread to distant organs.
This trial tests a new drug, QLC5508, against standard chemotherapy for people with advanced esophageal cancer that has already been treated. It aims to see if the new drug works better.
This Phase 2 trial tests penpulimab plus chemotherapy (with or without an added targeted pill called anlotinib) in people with advanced esophageal squamous cell carcinoma. It aims to slow tumor growth and improve outcomes, especially for patients who can’t have curative surgery or radiation.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a new treatment plan for people with advanced esophageal squamous cell carcinoma that has spread to lymph nodes but not to other organs. It aims to find the best way to treat this cancer using radiation and other therapies.
Hear when a new Advanced Oesophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.